Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The checkpoint inhibitor delayed disease progression and improved overall survival in non-small-cell lung cancer patients.
Nearly a quarter of patients treated with the peptide-drug conjugate experienced partial remission.
The Johnson & Johnson vaccine, which is easier to store and deliver, will help speed up the coronavirus vaccine rollout.
Bamlanivimab and etesevimab may be given to people with mild to moderate COVID-19 who are at high risk for progression to severe disease.
About a quarter of patients with advanced skin cancer experienced tumor shrinkage in a clinical trial.
Half of patients treated with Breyanzi experienced complete remission, and a majority of these responses were durable.
Umbralisib led to remission in 49% of patients with marginal zone lymphoma and 43% of those with follicular lymphoma.
The new targeted therapy was approved for non-small-cell lung cancer with a specific MET mutation.
The immunotherapy combination slowed disease progression and reduced the risk of death by 40%.
More than 80% of pediatric patients experienced complete remission in a small study.
The antibody-drug conjugate improved response rates and survival compared with chemotherapy.
COVID-19, FDA drug approvals and new approaches to treatment and quality of life stood out among this year’s top stories.
Orgovyx (relugolix) may eliminate some patients’ need to visit a clinic for treatments administered by a health care provider.
Tagrisso (osimertinib) was approved for non-small cell lung cancer patients with EGFR-positive tumors.
Xpovio (selinexor) was approved for adults with multiple myeloma who have received at least one prior therapy.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.